Literature DB >> 15188376

Induction of arthritis in HLA-DR4-humanized and HLA-DQ8-humanized mice by human cartilage proteoglycan aggrecan but only in the presence of an appropriate (non-MHC) genetic background.

Sándor Szántó1, Tamás Bárdos, Zoltán Szabó, Chella S David, Edit I Buzás, Katalin Mikecz, Tibor T Glant.   

Abstract

OBJECTIVE: To determine whether the rheumatoid arthritis (RA)-predisposing class II molecules of the major histocompatibility complex (MHC) can present cartilage proteoglycan (PG) aggrecan, and if so, to determine the epitope repertoire of the human cartilage PG in HLA-transgenic mice and determine whether HLA-transgenic mice develop arthritis in response to immunization with human cartilage PG.
METHODS: Mice transgenic for HLA-DR2.Ab(0), DR3.Ab(0), DR4.Ab(0), and DQ8.Ab(0), lacking their own (mouse) class II antigens (Ab(0)), on the original (arthritis-resistant) and the arthritis-susceptible BALB/c backgrounds, were immunized with human cartilage PG. The T cell epitope repertoire presented by these class II MHC alleles was determined using a synthetic peptide library (143 peptides of the core protein of human cartilage PG), and arthritis development was monitored and compared in wild-type and HLA-transgenic/congenic BALB/c mice.
RESULTS: Mice of the 4 HLA-transgenic lines, either on the original mixed, arthritis-resistant background or DR4.Ab(0)- and DQ8.Ab(0)-transgenic/congenic mice on the arthritis-susceptible BALB/c genetic background, responded well to PG immunization (as assessed by T cell responses and antibody and cytokine production), and a number of T cell epitopes along the core protein of human cartilage PG were identified. DR4.Ab(0)- and DQ8.Ab(0)-transgenic mice immunized with human cartilage PG developed arthritis, but only when these class II MHC molecules were present on the arthritis-susceptible (BALB/c) genetic background.
CONCLUSION: A number of human cartilage PG epitopes can be presented by HLA alleles that predispose to the development of RA, but the epitopes of the cartilage PG presented by HLA-DR4 or HLA-DQ8 can induce arthritis only in the presence of an appropriate genetic (non-MHC) background.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15188376     DOI: 10.1002/art.20285

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  16 in total

1.  Impaired activation-induced cell death promotes spontaneous arthritis in antigen (cartilage proteoglycan)-specific T cell receptor-transgenic mice.

Authors:  Ferenc Boldizsar; Katalin Kis-Toth; Oktavia Tarjanyi; Katalin Olasz; Akos Hegyi; Katalin Mikecz; Tibor T Glant
Journal:  Arthritis Rheum       Date:  2010-10

2.  An epitope-specific DerG-PG70 LEAPS vaccine modulates T cell responses and suppresses arthritis progression in two related murine models of rheumatoid arthritis.

Authors:  Katalin Mikecz; Tibor T Glant; Adrienn Markovics; Kenneth S Rosenthal; Julia Kurko; Roy E Carambula; Steve Cress; Harold L Steiner; Daniel H Zimmerman
Journal:  Vaccine       Date:  2017-06-03       Impact factor: 3.641

3.  T cell receptor (TCR) signal strength controls arthritis severity in proteoglycan-specific TCR transgenic mice.

Authors:  K Olasz; F Boldizsar; K Kis-Toth; O Tarjanyi; A Hegyi; W van Eden; T A Rauch; K Mikecz; T T Glant
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

4.  Arthritogenic T cells drive the recovery of autoantibody-producing B cell homeostasis and the adoptive transfer of arthritis in SCID mice.

Authors:  Katalin Kis-Toth; Marianna Radacs; Katalin Olasz; Willem van Eden; Katalin Mikecz; Tibor T Glant
Journal:  Int Immunol       Date:  2012-04-19       Impact factor: 4.823

5.  Proteoglycan-induced arthritis and recombinant human proteoglycan aggrecan G1 domain-induced arthritis in BALB/c mice resembling two subtypes of rheumatoid arthritis.

Authors:  Tibor T Glant; Marianna Radacs; Gyorgy Nagyeri; Katalin Olasz; Anna Laszlo; Ferenc Boldizsar; Akos Hegyi; Alison Finnegan; Katalin Mikecz
Journal:  Arthritis Rheum       Date:  2011-05

6.  Molecular manipulation with the arthritogenic epitopes of the G1 domain of human cartilage proteoglycan aggrecan.

Authors:  Y M Murad; Z Szabó; K Ludányi; T T Glant
Journal:  Clin Exp Immunol       Date:  2005-11       Impact factor: 4.330

7.  A longitudinal study on an autoimmune murine model of ankylosing spondylitis.

Authors:  T Bárdos; Z Szabó; M Czipri; C Vermes; M Tunyogi-Csapó; R M Urban; K Mikecz; T T Glant
Journal:  Ann Rheum Dis       Date:  2005-01-07       Impact factor: 19.103

8.  FTY720 (Gilenya) treatment prevents spontaneous autoimmune myocarditis and dilated cardiomyopathy in transgenic HLA-DQ8-BALB/c mice.

Authors:  Ferenc Boldizsar; Oktavia Tarjanyi; Katalin Olasz; Akos Hegyi; Katalin Mikecz; Tibor T Glant; Tibor A Rauch
Journal:  Cardiovasc Pathol       Date:  2016-05-17       Impact factor: 2.185

9.  Intramolecular polyspecificity in CD4 T-cell recognition of Ad-restricted epitopes of proteoglycan aggrecan.

Authors:  Jane Falconer; Katie Lowes; Anna L Furmanski; Julian Dyson; Wan Fai Ng; John H Robinson
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

10.  BALB/c mice genetically susceptible to proteoglycan-induced arthritis and spondylitis show colony-dependent differences in disease penetrance.

Authors:  Balint Farkas; Ferenc Boldizsar; Oktavia Tarjanyi; Anna Laszlo; Simon M Lin; Gabor Hutas; Beata Tryniszewska; Aaron Mangold; Gyorgy Nagyeri; Holly L Rosenzweig; Alison Finnegan; Katalin Mikecz; Tibor T Glant
Journal:  Arthritis Res Ther       Date:  2009-02-16       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.